• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

因果关系与黑素瘤分类。

Causation and melanoma classification.

机构信息

Department of Science and Technology Studies, University College London, Gower Street, London WC1E 6BT, UK.

出版信息

Theor Med Bioeth. 2011 Feb;32(1):19-32. doi: 10.1007/s11017-010-9168-3.

DOI:10.1007/s11017-010-9168-3
PMID:21190087
Abstract

In this article, I begin by giving a brief history of melanoma causation. I then discuss the current manner in which malignant melanoma is classified. In general, these systems of classification do not take account of the manner of tumour causation. Instead, they are based on phenomenological features of the tumour, such as size, spread, and morphology. I go on to suggest that misclassification of melanoma is a major problem in clinical practice. I therefore outline an alternative means of classifying these tumours based on causal factors. By analogy with similar systems that have recently emerged for other cancers, I suggest that this causal classification is likely to be both workable and helpful, even in the absence of a full causal-mechanistic understanding of the aetiology of the tumour.

摘要

在本文中,我首先简要介绍了黑色素瘤病因的历史。然后,我讨论了目前恶性黑色素瘤的分类方式。一般来说,这些分类系统并没有考虑肿瘤病因的方式,而是基于肿瘤的现象学特征,如大小、扩散和形态。我接着指出,黑色素瘤的误诊是临床实践中的一个主要问题。因此,我提出了一种基于病因的肿瘤分类方法。通过与最近出现的其他癌症的类似系统进行类比,我认为这种因果分类方法不仅可行,而且有用,即使我们对肿瘤的病因没有充分的因果机制理解。

相似文献

1
Causation and melanoma classification.因果关系与黑素瘤分类。
Theor Med Bioeth. 2011 Feb;32(1):19-32. doi: 10.1007/s11017-010-9168-3.
2
The classification of melanoma.fusion in dogs.犬黑色素瘤融合的分类
Minn Med. 1971 Jun;54(6):426-8.
3
Naming acquired melanocytic nevi. Unna's, Miescher's, Spitz's Clark's.
Am J Dermatopathol. 1990 Apr;12(2):193-209. doi: 10.1097/00000372-199004000-00012.
4
The classification of malignant melanoma.
Am J Dermatopathol. 1980 Winter;2(4):315-20. doi: 10.1097/00000372-198000240-00005.
5
Malignant melanoma: classification and staging of malignant melanoma.
Front Radiat Ther Oncol. 2006;39:149-158. doi: 10.1159/000090859.
6
Malignant melanoma microstaging. History, premises, methods, problems, and recommendations--a call for standardization.恶性黑色素瘤的微分期。历史、前提、方法、问题及建议——呼吁标准化
Pathol Annu. 1994;29 ( Pt 2):51-74.
7
Moles and melanoma: a history.痣与黑色素瘤:一段历史
Ann R Coll Surg Engl. 1994 Nov;76(6):373-80.
8
[TNM classification of malignant melanoma and non-melanoma skin cancer].[恶性黑色素瘤和非黑色素瘤皮肤癌的TNM分类]
Gan To Kagaku Ryoho. 1997 Nov;24(14):2163-9.
9
The biologic forms of malignant melanoma.恶性黑色素瘤的生物学形态
Hum Pathol. 1986 May;17(5):443-50. doi: 10.1016/s0046-8177(86)80032-6.
10
Classification of malignant melanomas: a view of the current controversy.恶性黑色素瘤的分类:当前争议之观点
Am J Dermatopathol. 1982 Oct;4(5):435-41. doi: 10.1097/00000372-198210000-00010.

本文引用的文献

1
Understanding mechanisms in the health sciences.理解健康科学中的机制。
Theor Med Bioeth. 2011 Feb;32(1):5-17. doi: 10.1007/s11017-010-9166-5.
2
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.初始导管原位癌诊断后生物标志物表达与后续肿瘤风险。
J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28.
3
Recent progress in understanding the pathology of malignant melanoma.恶性黑素瘤病理学研究的新进展。
J Pathol. 2009 Dec;219(4):400-9. doi: 10.1002/path.2617.
4
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.对具有K642E KIT突变的转移性黏膜黑色素瘤,伊马替尼呈现剂量依赖性完全缓解。
Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3. doi: 10.1111/j.1755-148X.2008.00475.x. Epub 2008 May 29.
5
Major response to imatinib mesylate in KIT-mutated melanoma.甲磺酸伊马替尼对KIT突变型黑色素瘤有显著疗效。
J Clin Oncol. 2008 Apr 20;26(12):2046-51. doi: 10.1200/JCO.2007.14.0707.
6
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.高剂量甲磺酸伊马替尼治疗转移性黑色素瘤的多中心II期试验:毒性显著但无临床疗效。
Cancer. 2006 May 1;106(9):2005-11. doi: 10.1002/cncr.21834.
7
Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma.2002年美国癌症联合委员会黑色素瘤分期系统的变化改变了各阶段特异性生存率的估计。
Cancer. 2006 Jan 1;106(1):163-71. doi: 10.1002/cncr.21594.
8
Distinct sets of genetic alterations in melanoma.黑色素瘤中不同的基因改变组合。
N Engl J Med. 2005 Nov 17;353(20):2135-47. doi: 10.1056/NEJMoa050092.
9
Sun exposure and mortality from melanoma.阳光照射与黑色素瘤死亡率
J Natl Cancer Inst. 2005 Feb 2;97(3):195-9. doi: 10.1093/jnci/dji019.
10
Malignant melanomas of the skin. A study of the origin, development, aetiology, spread, treatment, and prognosis.皮肤恶性黑色素瘤。关于起源、发展、病因、扩散、治疗及预后的研究。
Br J Plast Surg. 1962 Apr;15:97-116. doi: 10.1016/s0007-1226(62)80015-0.